Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways.

Wee P, Wang Z.

Cancers (Basel). 2017 May 17;9(5). pii: E52. doi: 10.3390/cancers9050052. Review.

2.

Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2.

Brijwani N, Jain M, Dhandapani M, Zahed F, Mukhopadhyay P, Biswas M, Khatri D, Radhakrishna VD, Majumder B, Radhakrishnan P, Thiyagarajan S.

Sci Rep. 2017 May 4;7(1):1502. doi: 10.1038/s41598-017-01566-x.

3.

RHBDD1 upregulates EGFR via the AP-1 pathway in colorectal cancer.

Miao F, Zhang M, Zhao Y, Li X, Yao R, Wu F, Huang R, Li K, Miao S, Ma C, Ju H, Song W, Wang L.

Oncotarget. 2017 Apr 11;8(15):25251-25260. doi: 10.18632/oncotarget.15694.

4.

EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics.

Yamamoto I, Nosho K, Kanno S, Igarashi H, Kurihara H, Ishigami K, Ishiguro K, Mitsuhashi K, Maruyama R, Koide H, Okuda H, Hasegawa T, Sukawa Y, Okita K, Takemasa I, Yamamoto H, Shinomura Y, Nakase H.

Oncotarget. 2017 Mar 14;8(11):17810-17818. doi: 10.18632/oncotarget.14863.

5.

Cudraflavone C Induces Tumor-Specific Apoptosis in Colorectal Cancer Cells through Inhibition of the Phosphoinositide 3-Kinase (PI3K)-AKT Pathway.

Soo HC, Chung FF, Lim KH, Yap VA, Bradshaw TD, Hii LW, Tan SH, See SJ, Tan YF, Leong CO, Mai CW.

PLoS One. 2017 Jan 20;12(1):e0170551. doi: 10.1371/journal.pone.0170551. eCollection 2017.

6.

Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern.

Al-Shamsi HO, Jones J, Fahmawi Y, Dahbour I, Tabash A, Abdel-Wahab R, Abousamra AO, Shaw KR, Xiao L, Hassan MM, Kipp BR, Kopetz S, Soliman AS, McWilliams RR, Wolff RA.

J Gastrointest Oncol. 2016 Dec;7(6):882-902. doi: 10.21037/jgo.2016.11.02.

7.

Mechanisms of resistance to anti-EGFR therapy in colorectal cancer.

Zhao B, Wang L, Qiu H, Zhang M, Sun L, Peng P, Yu Q, Yuan X.

Oncotarget. 2017 Jan 17;8(3):3980-4000. doi: 10.18632/oncotarget.14012.

8.
9.

MiR-384 inhibits human colorectal cancer metastasis by targeting KRAS and CDC42.

Wang YX, Chen YR, Liu SS, Ye YP, Jiao HL, Wang SY, Xiao ZY, Wei WT, Qiu JF, Liang L, Liao WT, Ding YQ.

Oncotarget. 2016 Dec 20;7(51):84826-84838. doi: 10.18632/oncotarget.12704.

10.

Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer.

Omolo B, Yang M, Lo FY, Schell MJ, Austin S, Howard K, Madan A, Yeatman TJ.

BMC Med Genomics. 2016 Oct 19;9(1):65.

11.

Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer.

Rankin A, Klempner SJ, Erlich R, Sun JX, Grothey A, Fakih M, George TJ Jr, Lee J, Ross JS, Stephens PJ, Miller VA, Ali SM, Schrock AB.

Oncologist. 2016 Sep 28. pii: theoncologist.2016-0148. [Epub ahead of print]

PMID:
27682134
12.
13.

Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer.

Sforza V, Martinelli E, Ciardiello F, Gambardella V, Napolitano S, Martini G, Della Corte C, Cardone C, Ferrara ML, Reginelli A, Liguori G, Belli G, Troiani T.

World J Gastroenterol. 2016 Jul 28;22(28):6345-61. doi: 10.3748/wjg.v22.i28.6345. Review.

14.

The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms.

Sievers CK, Kratz JD, Zurbriggen LD, LoConte NK, Lubner SJ, Uboha N, Mulkerin D, Matkowskyj KA, Deming DA.

Clin Colon Rectal Surg. 2016 Sep;29(3):232-8. doi: 10.1055/s-0036-1584292. Review.

PMID:
27582648
15.

Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy.

Nemecek R, Berkovcova J, Radova L, Kazda T, Mlcochova J, Vychytilova-Faltejskova P, Slaby O, Svoboda M.

Onco Targets Ther. 2016 Jul 28;9:4695-703. doi: 10.2147/OTT.S102891. eCollection 2016.

16.

In depth evaluation of the prognostic and predictive utility of PTEN immunohistochemistry in colorectal carcinomas: performance of three antibodies with emphasis on intracellular and intratumoral heterogeneity.

Ágoston EI, Micsik T, Ács B, Fekete K, Hahn O, Baranyai Z, Dede K, Bodoky G, Bursics A, Kulka J, Krenács T, Győrffy B, Harsányi L, Szász AM.

Diagn Pathol. 2016 Jul 8;11(1):61. doi: 10.1186/s13000-016-0508-0.

17.

Identification and characterization of EGF receptor in individual exosomes by fluorescence-activated vesicle sorting.

Higginbotham JN, Zhang Q, Jeppesen DK, Scott AM, Manning HC, Ochieng J, Franklin JL, Coffey RJ.

J Extracell Vesicles. 2016 Jun 24;5:29254. doi: 10.3402/jev.v5.29254. eCollection 2016.

18.

Blockage of Autophagy Rescues the Dual PI3K/mTOR Inhibitor BEZ235-induced Growth Inhibition of Colorectal Cancer Cells.

Oh I, Cho H, Lee Y, Cheon M, Park D, Lee Y.

Dev Reprod. 2016 Mar;20(1):1-10. doi: 10.12717/DR.2016.20.1.001.

19.

Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer.

Lee MS, McGuffey EJ, Morris JS, Manyam G, Baladandayuthapani V, Wei W, Morris VK, Overman MJ, Maru DM, Jiang ZQ, Hamilton SR, Kopetz S.

Br J Cancer. 2016 Jun 14;114(12):1352-61. doi: 10.1038/bjc.2016.87. Epub 2016 Jun 7.

20.

BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features.

Roma C, Rachiglio AM, Pasquale R, Fenizia F, Iannaccone A, Tatangelo F, Antinolfi G, Parrella P, Graziano P, Sabatino L, Colantuoni V, Botti G, Maiello E, Normanno N.

Cancer Biol Ther. 2016 Aug 2;17(8):840-8. doi: 10.1080/15384047.2016.1195048.

Supplemental Content

Support Center